- COMMENT
Take lessons from cancer evolution to the clinic
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 581, 382-383 (2020)
doi: https://doi.org/10.1038/d41586-020-01347-z
References
Jamal-Hanjani, M. et al. N. Engl. J. Med. 376, 2109–2121 (2017).
López, S. et al. Nature Genet. 52, 283–293 (2020).
Joshi, K. et al. Nature Med. 25, 1549–1559 (2019).
Ghorani, E. et al. Nature Cancer (in the press).
McGranahan, N. et al. Cell 171, 1259–1271 (2017).
Rosenthal, R. et al. Nature 567, 479–485 (2019).
de Koning, H. J. et al. N. Engl. J. Med. 382, 503–513 (2020).
Pignon, J.-P. et al. J. Clin. Oncol. 26, 3552–3559 (2008).
Abbosh, C. et al. Nature 545, 446–451 (2017).
AbdulJabbar, K. et al. Nature Med. (in the press).
Chemi, F. et al. Nature Med. 25, 1534–1539 (2019).
McFadden, D. G. et al. Proc. Natl Acad. Sci. USA 113, E6409–E6417 (2016).
Rozenblatt-Rosen, O. et al. Nature 550, 451–453 (2017).
Competing Interests
C.S. is a Royal Society Napier Professor and receives grant support from Pfizer, AstraZeneca, BMS, Roche-Venetana, Boehringer-Ingelheim and Ono Pharmaceutical. C.S. has consulted for Pfizer, Novartis, GlaxoSmithKline, MSD, BMS, Celgene, AstraZeneca, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi and the Sarah Cannon Research Institute. C.S. is a shareholder of Apogen Biotechnologies, Epic Bioscience and GRAIL, and has stock options in and is co-founder of Achilles Therapeutics, which is assessing the role of T cells targeting multiple trunk mutations in cancer cells. C.S. is co-inventor on a patent in that area (PCT/EP2016/059401). In relation to this article, C.S. holds a patent entitled ‘Method of detecting tumour recurrence’ (PCT/GB2017/053289) on assay technology to detect residual tumour DNA in blood, developed in collaboration with Natera, and has received funding support for MRD assay development from Natera and ArcherDx.